Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fi… (NCT06874894) | Clinical Trial Compass
By InvitationNot Applicable
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
South Korea1,021 participantsStarted 2022-05-25
Plain-language summary
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
Who can participate
Age range18 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
* Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
* Adults aged 18 or above who have provided consent for clinical information
Exclusion Criteria:
* Patients with moderate or severe mitral stenosis or mechanical prosthetic valve
What they're measuring
1
Clinical ischemic and hemorrhagic events
Timeframe: 12 months
Trial details
NCT IDNCT06874894
SponsorChung-Ang University Hosptial, Chung-Ang University College of Medicine